薬史学雑誌
Online ISSN : 2435-7529
Print ISSN : 0285-2314
ISSN-L : 0285-2314
承認審査過程の透明化 20 年の歩みと課題:新医薬品と新医療機器の審査報告書の公表を中心にして
森本 和滋川崎 聡子吉田 易範
著者情報
ジャーナル フリー

2015 年 50 巻 1 号 p. 64-77

詳細
抄録
For 20 years, the Ministry of Health, Labour and Welfare (MHLW, formerly Ministry of Health and Welfare (MHW)) has been trying to increase transparency of the review process for approving reports in order to promote the rational use of newly approved drugs and medical devices. The first Summary Basis of Approval (SBA) was published by MHW in 1994. In 1999, evaluation reports were prepared by MHW and the Pharmaceuticals and Medical Devices Evaluation Center to make them available to the public. In 2005, a notice from the Chief Executive of the Pharmaceuticals and Medical Devices Agency (PMDA) made procedures for public release of information on reviewing applications for new drugs. In 2006, 90 review reports of newly approved drugs and eight medical devices were revealed on PMDA websites. The dissemination of information by the United States Food and Drug Administration (FDA) and that of the European Medicines Agency (EMA) were studied and compared with that of the MHLW and PMDA. While common technical documents (CTD) for new drugs and summary technical documents (STED) for new medical devices have been released by PMDA, such documents are not released by the FDA and EMA. The European Public Assessment Report (EAPR) summary for the public is an interesting questionnaire approach that uses the What, How and Why format. Finally, future proposals for the next decade are also outlined. PMID: 26427100 [Indexed for MEDLINE]
著者関連情報
© 2015 日本薬史学会
前の記事 次の記事
feedback
Top